Immunotherapy using cytotoxic T cell and peptide vaccine for pancreatic cancer

(1) 15例（III期4例，Iva期8例，Ivb期3例）胰腺癌根治性切除后应用MUC1-CTL免疫治疗。只有1例患者出现肝脏复发。1年和2年生存率分别为80%和21.4%。这种免疫疗法可以预防术后肝转移，但不能控制局部复发。(2)我们开展了肿瘤肽疫苗治疗HLA-02和-24不可切除胰腺癌患者的I期研究。3毫克多肽与弗氏不完全佐剂一起皮下注射。未见严重不良反应。10例患者中有7例出现注射部位红肿。10例患者中有3例NC， 7例PD。一名NC患者仍然存活了12个月。该疫苗治疗可有效控制局部病变，包括局部淋巴结转移。

(1) Fifteen patients (stage III : 4, stage Iva : 8, stage Ivb : 3) with pancreatic cancer were treated by immunotherapy using MUC1-CTL after curative resection. Only one patient had liver recurrence. One year and 2 year survival rate were 80% and 21.4%, respectively. This immunotherapy may prevent liver metastasis after surgery, but can not control local recurrence.(2) We performed phase I study of cancer peptide vaccine therapy for HLA-02 and -24 patients with unresectable pancreatic cancer. Three mg of peptides were administered with Freund's incomplete adjuvant subcutaneously. No sever adverse effect was observed. Seven of 10 patients had redness and edema in the injection sites. Three of 10 patients had NC and 7 had PD. One NC patient is still alive for 12 month. This vaccine therapy may be effective to control local lesion including regional lymph node metastasis.